Emerade adrenaline pen recalled by health regulator

Anyone who uses the pens are being told to return them to pharmacies.

A BATCH OF adrenaline pens used to treat allergic reactions is being recalled.

The recall of the Emerade pens was announced today by the Health Products Regulatory Authority (HPRA).

The decision to recall a batch of the pens was made after some Emerade pens in other countries failed to produce an injection and failed to activate, with the potential for a blocked needle.

The pen is an emergency treatment for anaphylaxis.

The recall covers batches of:

150mcg pre-filled Emerade pens
300mcg pre-filled Emerade pens
500mcg pre-filled Emerade pens

Anyone who has an Emerade pen has been told by HPRA to return it to their local pharmacy and get it replaced with an alternative product.

The cause of the activation failure is unknown, as is rate of the defect in the pen.

Making a difference

A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation.

For the price of one cup of coffee each week you can make sure we can keep reliable, meaningful news open to everyone regardless of their ability to pay.

Support us Learn More

Emerade adrenaline pen recalled by health regulator

Making a difference

A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation.

Leave a commentcancel